Tislelizumab-jsgr (Tevimbra) coverage
Customize your policy alerts
Sign up for Health Net Policy CP PHAR.687 alerts
Get alerted when Policy CP PHAR.687 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for tislelizumab-jsgr (Tevimbra) for adults with specified malignancies and describes coding implications and approval durations for Health Net lines of business.
Added HCPCS code J9329 and removed HCPCS codes J3590 and C93991.
Updated criteria to include new indication for gastric/gastroesophageal junction adenocarcinoma (G/GEJ) in combination with platinum and fluoropyrimidine-based chemotherapy for PD-L1 positive tumors.
Updated criteria to include first-line ESCC treatment in combination with platinum-containing chemotherapy for PD-L1 positive tumors and added an option for planned esophagectomy as bypass for unresectable disease criterion.
Added HCPCS code J9329 and removed HCPCS codes J3590 and C93991.
Updated criteria to include new indication for G/GEJ and first-line ESCC treatment in combination with platinum-containing chemotherapy for tumors expressing PD-L1; added multiple off-label indications supported by NCCN.
For HCC, clarified criterion as first-line systemic therapy and added option to be prescribed as subsequent-line systemic therapy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.